Punjab bans Coldrif, even as PIL in SC seeks probe on cough syrup deaths

With this, the state joins Maharashtra, Kerala and Tamil Nadu, who have already announced bans on the cough syrup

Cough syrup
According to people in the know, several states are checking if the syrup from the indicated batch has been dispensed in their jurisdictions, with some even checking samples of all brands of cough syrup for contamination. (Photo: AdobeStock)
Sanket KoulPTI New Delhi
2 min read Last Updated : Oct 07 2025 | 10:45 PM IST
The Punjab government on Tuesday banned the sale, distribution and use of Coldrif cough syrup in the state in the wake of the deaths of 14 children in Chhindwara district of Madhya Pradesh allegedly due to the consumption of the contaminated medicine.
 
“The aforementioned drug formulation (Coldrif) is reported to be adulterated, as it contains DEG (46.28 per cent weight per volume), which makes it injurious to health,” the Punjab food and drug administration (FDA) said in its order.
 
With this, the state joins Maharashtra, Kerala and Tamil Nadu, who have already announced bans on the cough syrup. Other states such as Karnataka and Telangana have sounded alerts, asking all health officers to sensitise the public on use of cough syrups.
 
According to people in the know, several states are checking if the syrup from the indicated batch has been dispensed in their jurisdictions, with some even checking samples of all brands of cough syrup for contamination.
 
Meanwhile, a public interest litigation (PIL) has been filed in the Supreme Court seeking inquiry and systemic reform in drug safety mechanisms.
 
The PIL, filed by advocate Vishal Tiwari, seeks a court-monitored probe into the incidents and urges the constitution of a national judicial commission or expert committee headed by a retired Supreme Court judge.
 
The petition also contends that separate state-level investigations have led to fragmented accountability, enabling repeated lapses that allow hazardous formulations to reach the market.
 
The trouble for Coldrif began after a batch of the medicine manufactured by a Kancheepuram-based unit was found to have contaminants such as Diethylene Glycol (DEG) by the Tamil Nadu FDA. 
 
Regulatory action has been taken against the unit where this particular sample of Coldrif was manufactured, with cancellation of the manufacturing licence and initiation of criminal proceedings being recommended by drug regulator CDSCO based on inspection findings.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :PharmaCough syrup

First Published: Oct 07 2025 | 8:17 PM IST

Next Story